- Investing Ideas
- /
- Hong Kong Biotech Breakthroughs
Hong Kong Biotech Breakthroughs
Results
13
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
13 companies
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$113.9b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$488.60
7D
-13.0%
1Y
153.3%
CARsgen Therapeutics Holdings
Market Cap: HK$10.0b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$18.04
7D
-3.9%
1Y
279.8%
Ascentage Pharma Group International
Market Cap: HK$26.6b
A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
6855
HK$72.50
7D
-5.6%
1Y
72.2%
RemeGen
Market Cap: HK$54.5b
A biopharmaceutical company, discovers, develops, produces and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.
9995
HK$93.35
7D
-24.7%
1Y
525.7%
Akeso
Market Cap: HK$117.9b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$128.00
7D
-9.4%
1Y
98.4%
Cutia Therapeutics
Market Cap: HK$3.0b
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$8.64
7D
-3.0%
1Y
-33.5%
Beijing Luzhu Biotechnology
Market Cap: HK$5.0b
A biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in Mainland China.
2480
HK$25.00
7D
3.9%
1Y
1.0%
Everest Medicines
Market Cap: HK$18.8b
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
1952
HK$53.20
7D
-5.3%
1Y
116.7%
CStone Pharmaceuticals
Market Cap: HK$10.0b
A biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally.
2616
HK$6.80
7D
-14.0%
1Y
293.1%
Nanjing Leads Biolabs
Market Cap: HK$13.9b
A clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide.
9887
HK$69.90
7D
-3.8%
1Y
n/a
InnoCare Pharma
Market Cap: HK$29.1b
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.
9969
HK$14.71
7D
-22.2%
1Y
113.2%
CanSino Biologics
Market Cap: HK$15.8b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$47.00
7D
-9.8%
1Y
80.8%
Mirxes Holding
Market Cap: HK$18.4b
A micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China.
2629
HK$67.45
7D
-8.0%
1Y
n/a